Menu

Filter articles published since 2015 by topic, disease, or article type.

Guidlines for filtering

Results are filtered to show all matching articles from a particular category, and to show only articles that match all selected categories.

For instance, if "Biomarkers" and "Genetics" are selected in the Topic category, and "Multiple sclerosis" is selected in the Disease category, all results that match EITHER the Biomarkers OR Genetics Topic category will be shown, but only if they also match the Multiple sclerosis Disease category; i.e. Boolean search of [("Biomarkers" OR "Genetics") AND "multiple sclerosis"]

Filter articles published since 2015 by topic, disease, or article type.

Guidlines for filtering

Results are filtered to show all matching articles from a particular category, and to show only articles that match all selected categories.

For instance, if "Biomarkers" and "Genetics" are selected in the Topic category, and "Multiple sclerosis" is selected in the Disease category, all results that match EITHER the Biomarkers OR Genetics Topic category will be shown, but only if they also match the Multiple sclerosis Disease category; i.e. Boolean search of [("Biomarkers" OR "Genetics") AND "multiple sclerosis"]

Neuralstem CEO Celebrates Progress and Looks To the Future

Neuralstem’s CEO Richard Garr recently reflected on the substantial progress the company has made since embarking on a “journey … to find a potential treatment for ALS.” In his blog post, Garr commented on the presentation that Dr. Eva Feldman, principal investigator on the Neuralstem Phase I trial and the upcoming Phase II trial, gave at the Canadian Neurological Sciences Federation’s Annual Congress in June. During her presentation Dr. Feldman chose to focus on the “remarkable surgical feat involved in this therapy”, which is often overlooked and “taken for granted.” For example there are extreme technical challenges involved with injecting stem cells into the spinal cord, in an area so small it is “the equivalent of hitting the chin on President Roosevelt’s face on [a] dime.” Also, Dr. Feldman spoke about the exciting expansion of the Phase II trial to include more patients who can be treated with “more cells” at two additional centers. Garr noted that “the FDA is getting comfortable with this ground breaking technology and totally new approach to treating this terrible disease.” Clearly great “progress” indeed.

Neuralstem’s CEO Richard Garr recently reflected on the substantial progress the company has made since embarking on a “journey … to find a potential treatment for ALS.” In his blog post, Garr commented on the presentation that Dr. Eva Feldman, principal investigator on the Neuralstem Phase I trial and the upcoming Phase II trial, gave at the Canadian Neurological Sciences Federation’s Annual Congress in June. During her presentation Dr. Feldman chose to focus on the “remarkable surgical feat involved in this therapy”, which is often overlooked and “taken for granted.” For example there are extreme technical challenges involved with injecting stem cells into the spinal cord, in an area so small it is “the equivalent of hitting the chin on President Roosevelt’s face on [a] dime.” Also, Dr. Feldman spoke about the exciting expansion of the Phase II trial to include more patients who can be treated with “more cells” at two additional centers. Garr noted that “the FDA is getting comfortable with this ground breaking technology and totally new approach to treating this terrible disease.” Clearly great “progress” indeed.

Post navigation

Filter articles published since 2015 by topic, disease, or article type.

Guidlines for filtering

Results are filtered to show all matching articles from a particular category, and to show only articles that match all selected categories.

For instance, if "Biomarkers" and "Genetics" are selected in the Topic category, and "Multiple sclerosis" is selected in the Disease category, all results that match EITHER the Biomarkers OR Genetics Topic category will be shown, but only if they also match the Multiple sclerosis Disease category; i.e. Boolean search of [("Biomarkers" OR "Genetics") AND "multiple sclerosis"]